Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 3/20 | 0.51 |
| ▸ | CDK1 | P06493 | 3/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22161378 | 0.83 | TUBB4A (0.49) | MTNR1AMTNR1BTUBB4ATUBBTUBA3C | |
| SCHEMBL22160195 | 0.77 | TACR1 (0.51) | — | |
| SCHEMBL22160460 | 0.76 | APOL1 (0.49) | — | |
| SCHEMBL30184436 | 0.76 | APOL1 (0.49) | — | |
| SCHEMBL29033496 | 0.73 | MTNR1A (0.53) | MTNR1AMTNR1BTUBB4ATUBBTUBA3C | |
| SCHEMBL22747549 | 0.73 | MTNR1A (0.53) | MTNR1AMTNR1BTUBB4ATUBBTUBA3C | |
| SCHEMBL9274444 | 0.72 | GPR35 (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29033495 | 0.71 | PTGS2 (0.46) | GSK3BMTNR1AMTNR1BTUBB4ATUBB | |
| SCHEMBL15331091 | 0.71 | KIF11 (0.46) | MAPTKIF11 | |
| SCHEMBL29033499 | 0.70 | CCNC (0.50) | MTNR1AMTNR1BTUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
| WO-2020131807-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | CCNB2 3155/4885CDK1 1710/4885CCNB1 2472/4885 |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | CCNB2 3327/4885CDK1 1661/4885CCNB1 2627/4885 |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, SAAL1, LOXL1 | CCNB2 3079/4885CDK1 2255/4885CCNB1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.